Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pitrakinra - Aerovance

Drug Profile

Pitrakinra - Aerovance

Alternative Names: AER-001; Aeroderm; Aerovant; BAY-16-9996; non-PEGylated AER-001; non-PEGylated pitrakinra

Latest Information Update: 19 Jun 2015

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Bayer
  • Developer Aerovance; Bayer
  • Class Antiasthmatics
  • Mechanism of Action Interleukin 13 receptor antagonists; Interleukin 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute asthma; Allergic asthma; Asthma; Atopic dermatitis

Most Recent Events

  • 08 Jun 2010 Aerovance shares phase IIb data with potential partners
  • 08 Jun 2010 Top-line efficacy and adverse events data from the phase IIb AeroTrial trial in asthma released by Aerovance
  • 03 Nov 2009 Aerovance completes enrolment in the phase IIb AeroTrial for Asthma in USA, UK, Hungary & Poland (NCT00801853)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top